Mechanisms of Chemotherapy/Radiotherapy-Induced Emesis in Animal Models

Oncology (Switzerland)

Volumn 53, Issue 1, 1996, Pages 8-17

  Naylor, R J ^a   Rudd, J A ^b  

^a School of Pharmacy   (United Kingdom)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Animal model; Chemotherapy; Delayed emesis; Emesis; Radiotherapy

Indexed keywords

ANTIEMETIC AGENT; ATROPINE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; IBUPROFEN; INDOMETACIN; METOCLOPRAMIDE; ONDANSETRON; SCOPOLAMINE; SEROTONIN; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; ZACOPRIDE;

ANIMAL MODEL; ANTIEMETIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONFERENCE PAPER; DRUG MECHANISM; ENTEROCHROMAFFIN CELL; FERRET; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; SEROTONIN RELEASE; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; RADIOTHERAPY; VOMITING;

EID: 0029788231     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227634     Document Type: Article

References (77)

1. Akwari OH: The gastrointestinal tract in chemo-therapy-induced cmesis, A final common pathway, Drugs 1983;25(suppl 1): 18-34.
2. Allan SG, Combleet MN, Warrington PS, Golland IM, Leonard RCF, Smyth JF: Dexamctliasonc and high dose metoclopramide: Efficacy in controlling cisplatin-induccd nausea and vomiting, Br Med J 1984;289:878-879.
3. Andrews PLR, Bhandari P, Garland S, Bingham S, Davis CJ, Hawthorn J, Davidson HIM, Roy-lancc R, I.ane S: Docs retching have a function? An experimental study in the ferret, Pharmaco-dyn Thcr 1990a;9:135-152.
4. Andrews PLR, Blower PR: The Ideal Anticmctic for the Cancer Patient - Preclinical Profile, SmithKline Beecham Satellite Symposium ESMO, 1992, pp 6-11.
5. Andrews PLR, Blower PR: The Physiology of Cytotoxic-Induced Emesis: New Insights, Smith Kline Beecham Satellite Symposium ECC07, Jerusalem 1994, pp 14-17.
6. Andrews PLR, Davis CL, Bingham S, Davidson HIM, Hawthorn J, Maskell L: The abdominal visceral innervation and the emetic reflex: Pathways, pharmacology and plasticity, Can J Physiol Pharmacol 1990b:68:325-345.
7. Andrews PLR, Rapcport WG, Sanger GJ: Ncuro-pharmacology of cmesis induced by anti-cancer therapy, Trends Pharmacol Sci 1988,9:334-341.
8. Andrykowski MA, Redd WH, Hatfield AK: Development of anticipatory nausea: A prospective analysis, J Consult Clin Psychol 1985:53:447-454.
9. Barnes JM, Barnes NM, Costall B, Deakin JFW, Ironside JW, Kilpatrick GJ, Naylor RJ, Rudd JA, Simpson MDC, Slater P, Tycrs MB: Identification and distribution of 5-117\ recognition sites within the human brainstem, Neurosci Lett 1990:11:80-86.
10. Barnes NM, Bunce KT, Naylor RJ, Rudd JA: The actions of fcntanyl to inhibit drug-induced cmesis, Neuropharmacology 1991:30:1073-1083.
11. Bermudez J, Boyle EA, Miner WD, Sanger GJ: The anti-emetic potential of the 5-hydroxytrypta-mine receptor antagonist BRL43694, Br J Cancer 1988;58:644-650.
12. Boyle EA, Miner WD, Sanger GJ: Different anticancer therapies evoke cmesis by mechanisms that can be blocked by the 5-IITj receptor antagonist BRL43694, Br J Pharmacol 1987; 91:418P.
13. Bradley PB, Engel G, Fenuik W: Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptaminc, Neuropharmacology 1986;25:563-576.
14. Buchheit KH, Buschner HH, Gamse R: The anti-emetic profile of the 5-HT? receptor antagonist ICS-205930 and its quaternary derivative, 2nd IUPHAR Meeting on Serotonin, Basel, July 1990, p 148.
15. Butcher ME: Global experience with ondansetron and future potential, Oncology 1993:50:191 - 197.
16. Butler A, Elswood CJ, Burridge J, Ireland SJ, Bunce KT, Kilpatrick GJ, Tyers MB: The pharmacological characterisation of 5-HTi receptors in three isolated preparations derived from guin-ca-pig tissues, Br J Pharmacol 1990:101:591-598.
17. Butler A, Hill JM, Ireland SJ, Jordan CC, Tyers MB: Pharmacological properties of GR3S032F, a novel antagonist at 5-HTj receptors, Br J Pharmacol 1988;94:397-412.
18. Carpenter DO, Briggs DB, Knox AP, Strominger NL: Radiation-induced emesis in the dog: Effects of lesions and drugs, Radiat Res 1986; 108:307-316.
19. Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, Tattcrsal MHN: On the receiving end - patient perception of the side effects of cancer chemotherapy, Eur J Cancer Clin Oncol 1983;19:203-208.
20. Coggon D, Inskip H: Is there an epidemic of cancer? BMJ 1994;308:705-708.
21. Costall B, Domcney AM, Naylor RA, Tattcrsall FD: 5-Hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis, Neuropharmacology 1986.25:959-961.
22. Costall B, Domcney AM, Naylor RJ, Tattcrsall FD: Emesis induced by cisplatin in the ferret as a model for the detection of anti-emctic drugs, Neuropharmacology 1987:9:1321-1326.
23. Cubcddu LX, Hoffman IS, Fucnmayor NT, Finn AL: Efficacy of ondansetron (GR38032F) and the role of serotonin in cisplatin-induced nausea and vomiting, N Engl J Med 1990:322: 810-816.
24. Davidson HIM, Pilot MA: Changes in gastrointestinal motility associated with nausea and vomiting; in Andrews PLR, Sanger GJ (eds): Emc-sis in Anti-Cancer Therapy: Mechanisms and Treatment, London, Chapman Hall, 1993, pp 71-87.
25. Davis CJ, Harding RK, Leslie RA, Andrews PLR: The organisation and vomiting as a protective reflex; in Davis CJ, Lakc-Bakaar GV, Gra-hamc-Smith DG (eds): Nausea and Vomiting: Mechanisms and Treatment, Berlin, Springer, 1986, pp 65-75.
26. Florczyk AP, Schurig JE, Bradncr WT: Cisplatin-induced emesis in the ferret: A new animal model, CancerTrcat Rep 1982:66:187-189.
27. Fozard J, Mobarok-Ali ATM: Blockade of neuronal tryptamine receptors by mctoclopramide, Eur J Pharmacol 1978;49:109-112.
28. Freeman AJ, Boubtra C, Dale TJ, Gardner CJ, Twissell DJ: The vomiting reflex and the role of 5-HTi receptors, Anticancer Drugs 1993:4 (suppl 2):9-15.
29. Fukuda H, Koga T: The Botzingcr complex as the pattern generator for retching and vomiting in the dog, Ncurosci Res 1991;12:471-485.
30. Gaddum JH, Picarelli ZP: Two kinds of tryptamine receptor, Br J Pharmacol 1957; 12:323-328.
31. 3 and 5-HT4 reccptors of the release of 5-hydroxytryptamine from the guinea-pig small intestine, Naunyn Schmiedebergs Arch Pharmacol 1993;347:137-140.
32. Gores TJ, Liposits Z, Palay SL, Chan-Palay V: Serotonin neurons on the ventral brain surface, Proc Natl Acad Sci USA 1985:82:7449-7452.
33. Gralla RJ, Itri LM, Pisko SE, Squillante AE, Kelscn DP, Braun DW, Bordin LA, Braun TJ, Young CW: Anticmetic efficacy of high-dose mctoclopramide: Randomized trials with placcbo and prochlorperazine in patients with chemothcra-py-induccd nausea and vomiting, N Engl J Med 1981:305:905-909.
34. Grundy D, Blackshaw A, Andrews PLR: Neural correlates of the gastrointestinal motor changes in emesis: in Tachc Y, Wingate D (eds): Brain-Gut Interactions, Boca Raton, CRC Press,1991, pp 325-328.
35. Gylys JA, Doran KM, Buyniski JP: Antagonism of cisplatin-induced emesis in the dog, Res Com-mun Chem Pathol Pharmacol 1979;23:61-68.
36. Harris AL: Cytotoxic therapy-induccd vomiting is mediated via enkephalin pathways, Lancet 1982:i:714-716.
37. Hawthorn J, Cunningham D: Dcxamethasone can potentiate the action of a 5-HTi rcceptor antagonist 011 cyclophosphamide-induced vomiting in the ferret, Br J Canccr 1990:61:56-60.
38. Hawthorn J, Ostler KJ, Andrews PLR: The role of the abdominal visceral innervation and 5-hy-droxytryptaminc-M reccptors in vomiting induced by the cytotoxic drugs cyclophospha-midc and cisplatin in the ferret, Q J Exp Physiol 1988;73:7-21.
39. Higgins GA, Kilpatrick GJ, Bunce KT, Jones BJ, Tyers MB: 5-HTj receptor antagonists injected into the area postrema inhibit cisplatin-in-duccd emesis in the ferret, Br J Pharmacol 1989;97:247-255.
40. Hoagland AC, Bcnnct JM, Morrow GR, Carnrike CLM: Oncologist’s view of cancer patients’ non-compliance, Am J Oncol 1983;6:239-244.
41. Humphrey PPA, Hartig P, Hoyer D: A proposed new nomenclature for 5-HT receptors, Trends Pharmacol Sci 1993;14:233-236.
42. Ireland J, Tyers MB: Pharmacological characterization of 5-hydroxytryptamine-induced depolarization of the rat isolated vagus nerve, Br J Pharmacol 1987;90:229-238.
43. Kilpatrick GJ, Jones BJ, Tyers MB: The distribution of specific binding of the 5-HTi receptor ligand pH] GR65630 in rat brain using quantitative autoradiography, Neurosci Lett 1988:94: 156-160.
44. King FD, Sanger GJ: 5-HTj rcceptor antagonists, Drugs of the Future 1989; 14:875-889.
45. King GL: Characterization of radiation-induced emesis in the ferret, Radiat Res 1988; 1 14:599-612.
46. Kris MG, Gralla RJ, Clark RA, Tyson LB, O’Connell JP, Wertheim MS, Kelscn DP: Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin, J Clin Oncol 1985:3:1379-1384.
47. Laszlo J, Lucas VSJ: Emesis as a critical problem in chemotherapy, N Engl J Med 1981:305:948-949.
48. Lawes N: The origin of the vomiting response: A ncuroanatomical hypothesis, Can J Physiol Pharmacol 1990;68:254-259.
49. Lee KY, Park HJ, Chey WY: Studies of mechanisms of retching and vomiting in dogs, Dig DisSci 1985:30:22-28.
50. Leslie RA, Reynolds DJM, Andrews PLR, Gra-hame-Smith DG, Davis CJ, Harvey JM: Evidence for prcsynaptic 5-hydroxytryptamine recognition sites on vagal afferent terminals in the brainstem of the ferret, Neuroscience 1990: 38:667-673.
51. Longo DL, Wesley M, Howscr D, Hubbard SM, Anderson T, Young RC: Results of a randomised double-blind crossover trial of scopolamine versus placcbo administered by trans-dermal patch for the control of cisplatin-in-duced emesis.CancerTrcat Rep 1985:66:175-176.
52. Milano S, Grelot L, Chen Z, Bianchi AL: Vagal-induced vomiting in deccrcbrate cat is not suppressed by specific 5-HTs receptor antagonists, J Auton Nerv Syst 1990;31:109-118.
53. Miller AD, Wilson VJ: ‘Vomiting center’ reanalyzed: An clcctrical stimulation study, Brain Res 1983:270:154-158.
54. Miner WD, Sanger GJ: Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryp-taminc M-receptor antagonism, Br J Pharmacol 1986;88:497-499.
55. Morran C, Smith DC, Anderson DA, McArdle CS: Incidence of nausea and vomiting with cytotoxic chemotherapy: A prospective randomised trial of anti-emetics, Br Med J 1979; 1:1323-1324.
56. Neimegeers CJE: The apomorphine antagonism test in dogs, Pharmacology 1971;6:353-364.
57. Nesse RM, Carli T, Curtis GC, Klienman PD: Pre-treatment nausea in canccr chemotherapy: A conditioned response? Psychosom Med 1980; 42:43-46.
58. Palmer MC, Colls BM: Amelioration of cytotoxic-induced emesis with high-dose mctoclopramide, dcxamcthasonc and lorazepam, Canccr Chcmother Pharmacol 1987;19:331-334.
59. Pratt GD, Bowery NG, Kilpatrick KGJ, Leslie RA, Barnes NM, Naylor RA, Jones BJ, Nelson DR, Palacios JM, Slater P, Reynolds J M: Consensus meeting agrees distribution of 5-HT* receptors in mammalian hindbrain, Trends Pharmacol Sci 1990;11:135-137.
60. Reiser G, Hamprecht B: Substance P and serotonin synergistically activate a cation permeability in a neuronal cell line, Naunyn Schmicdcbcrgs Arch Pharmacol 1988;337(suppl):R109.
61. Reynolds DJM, Leslie RA, Grahame-Smith DG, Harvey JM: Localization of 5-HTi receptor binding sites in human dorsal vagal complex, Eur J Pharmacol 1989:174:127-130.
62. Rich WM, Abdulhayoglu G, DiSaia PJ: Mcthyl-prcdnisolone as an anticmetic drug during canccr chemotherapy - A pilot study, Gynecol Oncol 1980;9:193-198.
63. Roberts JT, Priestman TJ: A review of ondansetron in the management of radiothcrapy-induccd emesis, Oncology 1993:50:0.
64. Robertson DW, Cohen ML, Krushinski JH: LY191617, a 5-HTi rcceptor antagonist which docs not cross the blood-brain barrier, 2nd IUPHAR Meeting on Serotonin, Basel, July1990, p 149.
65. Roila F, Tonato M, Cognctti F, Cortesi E, Favalli G, Marangolo M, Amadori D, Bella MA, Gra-mazio V, Donati D, Ballatori E, Del Favcro A: Prevention of cisplatin-induced emesis: A dou-ble-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone, J Clin Oncol 1991:9:675-678.
66. Roylance RR, Andrews PLR, Hawthorn J, Bingham S, Davidson HI: The antiemetic effects of atropine sulphate in the ferret, Br J Pharmacol 1989.96:330P.
67. Rudd JA Jordan CC, Naylor RJ: Profiles of emetic action of cisplatin in the ferret, A potential model of acute and delayed emesis, Eur J Pharmacol 1994:262:R1-R2.
68. Rufif P, Paska W, Goedhals L, Pouillart P, Riviere A, Vorobiof D, Bloch B, Jones A, Martin C, Brunet R, Butcher M, Forster J, McQuade B: Ondansetron compared with granisetron in the prophylaxis of cisplatin-induccd acute emesis: A multicentre double-blind, randomised, par-allel-group study, Oncology 1994;51:113-118.
69. Schworer H, Racke K, Kilbinger H: Cisplatin increases the release of 5-hydroxytryptaminc (5-HT) from the isolated perfused small intestine of the guinea-pig: Involvement of 5-HTj receptors, Naunyn Schmiedebergs Arch Pharmacol 1991:344:143-149.
70. Smith WL, Alphin RS, Jackson CB, Sancilio LF: The anti-cmctic profile of zacopridc, J Pharm Pharmacol 1989;41:101-105.
71. Smith WL, Callaham EM, Alphin RS: The cmctic activity of centrally administered cisplatin in cats and its antagonism by zacopridc, J Phar-mac Pharmacol 1988:40:142-143.
72. Smyth JF, Coleman RE, Nicoloson M, Gallmeier WM, Leonard RCF, Cornbleet MA, Allan SG, Upadhyaya BK, Bruntsch U: Does dcxametha-sone enhance control of acute cisplatin-in-duced emesis by ondansetron? BMJ 1991:303: 1423-1426.
73. Stables R, Andrews PLR, Bailey HE, Costall B, Gunning SJ, Hawthorn J, Naylor RJ, Tyers MB: Antiemetic properties of the 5-HTj receptor antagonist GR38032F, Cancer Treat Rep 1987;14:333-336.
74. Stryker JA, Demers LM, Mortel R: Prophylactic iboprufen administration during pelvic irradiation, Int J Radiat Oncol Biol Phys 1979:5: 2049-2052.
75. Tiley C, Powcls R, Catalano J, Trelcavcn J, Eshclby J, Hewctson M, Tait D, Cunningham D: Re-sultsof a double-blind placebo-controlled study of ondansetron as an antiemetic during total body irradiation in patients undergoing bone marrow transplantation, Leuk Lymphoma 1992;7:317-321.
76. 4 receptors are not involved in emesis in the ferret, Br J Pharmacol 1994; 113:22P.
77. Wang SC, Borison HL: The vomiting center, A critical experimental analysis, Arch Neurol Psychiatry 1950;63:928-941.